Abstract Details

Title Multiple Sclerosis Phenotypes Display Divergent Dynamic Functional Connectivity Abnormalities for Thalamic Sub-Regions

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 312

Objective To assess dynamic functional connectivity (dFC) for thalamic sub-regions (frontal, motor, occipital, postcentral and temporal) in multiple sclerosis (MS) according to clinical phenotype and to explore the association between dFC abnormalities and disability.

Background dFC is a useful technique to capture time-varying properties of resting state (RS) functional connectivity (FC). Thalamus as a whole showed abnormal dFC in multiple sclerosis (MS). However, thalamus is a complex structure constituted by neuronal groups, each one with a specific static FC pattern.

Design/Methods 89 patients (49 relapsing-remitting [RR] MS; 40 progressive [P] MS) and 53 matched healthy controls (HCs) performed neurological, neuropsychological and RS fMRI assessment. dFC for thalamic sub-regions was measured as standard deviation of FC across sliding windows.

Results MS patients showed an overall reduced dFC vs HCs between most of thalamic sub-regions and fronto-temporo-occipital regions. In addition, PMS also exhibited increased dFC vs HCs and RRMS between posterior thalamic sub-regions and occipito-temporo-insular cortices. Cognitively impaired patients showed an increased dFC between the left motor thalamic sub-region and right insular cortex, between the left occipital thalamic sub-region and right precentral and calcarine cortex, and between the left temporal thalamic sub-region and left thalamus/caudate nucleus vs cognitively preserved patients. While RRMS showed a more severe clinical disability correlated with reduced dFC between the left postcentral thalamic sub-region and right inferior frontal cortex, in PMS, more severe clinical disability correlated with increased dFC between right postcentral/left frontal thalamic sub-regions and left occipital/right insular cortices.

Conclusions Differently from RRMS showing reduced dFC for almost all thalamic sub-regions, PMS showed reduced dFC for anterior thalamic sub-regions and increased dFC for posterior thalamic sub-regions (associated with more severe disability). Increased dFC possibly reflects the exhaustion of plasticity mechanisms counteracting disease pathology reflecting instable functional connections especially for posterior thalamic sub-regions.

Authors/Disclosures
Paolo Preziosa (Ospedale San Raffaele) PRESENTER	Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Paola Valsasina	Paola Valsasina has nothing to disclose.
Antonio Carotenuto	Mr. Carotenuto has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merk, Novartis, Roche and Almirall. The institution of Mr. Carotenuto has received research support from ALMIRALL. The institution of Mr. Carotenuto has received research support from Carotenuto Antonio.
Milagros Hidalgo de la Cruz	Milagros Hidalgo de la Cruz has nothing to disclose.
Laura Cacciaguerra, MD, PhD (Mayo Clinic)	Dr. Cacciaguerra has nothing to disclose.
	No disclosure on file
Maria A. Rocca (Neuroimaging Research Unit)	Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

��ɫ��

��ɫ��